- NCIt
- C2960
Loading cancer entity…
Loading cancer entity…
Clinical trials
67 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06866574 | A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males | active not recruiting | Phase 3 | 9,300 | Xiamen UniversityOTHER | 1 | Jul 31, 2025 | clinicaltrials |
| NCT06465914 | A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males | active not recruiting | Phase 3 | 9,000 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Dec 12, 2024 | clinicaltrials |
| NCT02653118 | Long-term Follow-up of Broad Spectrum Human Papillomavirus (HPV) Vaccine Study in Women (V503-021) | active not recruiting | — | 4,453 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Nov 12, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2025source: clinicaltrials
| NCT05314023 |
| Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053) |
| active not recruiting |
| Phase 3 |
| 1,590 |
| Merck Sharp & Dohme LLCINDUSTRY |
| 1 |
| Jan 19, 2023 |
| clinicaltrials |